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This is our second symposium on the future direc- 
tions of immunoglobulin therapy. While the first 
symposium explored the mechanisms of action of 
intravenous immune globulin (IVIG) and its use in 
various clinical disorders, this symposium has 
taken a new direction in reviewing the potential 
therapeutic role of monoclonal antibodies in the 
treatment of malignancy and autoimmune dis- 
eases. 
It has been 16 years since K6hler and Milstein 
(1) successfully immortalized antibody-producing 
cells by fusing them with mouse myeloma cells. 
The ability to generate hybridoma cell lines pro- 
ducing a specific antibody has provided the tools 
which have had far-reaching implications in many 
areas of basic and clinical medicine. Dr. Matthew 
Scharff reviewed the fascinating history of mono- 
clonal antibodies and the current state of hybrid- 
oma technology. For years scientists have been 
looking for " the  magic bullet" for the treatment of 
malignant disorders. The concept of a specific 
immunotoxin, an extremely potent poison conju- 
gated to a monoclonal antibody, has initiated a 
new era in cancer chemotherapy. Recent advances 
in monoclonal antibody methodologies, recombi- 
nant DNA, and gene transfer technologies have 
enabled scientists to genetically engineer antibody 
molecules with highly potent toxins. Drs. Ellen 
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Vitetta and Thomas Waldmann reviewed their 
investigations and clinical experience with this 
exciting, novel approach in creating a whole new 
class of immunotoxins for use in cancer chemo- 
therapy. Dr. Larry Steinman presented his work 
on the use of monoclonal antibodies as new tools 
in better understanding the immunobiology of 
autoimmune neurologic diseases and as potential 
therapeutic agents. 
Despite marked improvement in the survival 
rate of preterm infants in recent years,  infection 
remains a major problem because of the difficulty 
in making a rapid and accurate diagnosis and the 
fact that the neonate is an immunocompromised 
host. It was not difficult to extrapolate the expe- 
rience of using IVIG as replacement therapy in 
patients with primary immune deficiencies to 
other types of acquired or secondary immunoglob- 
utin deficiencies. The hypogammaglobulinemia of 
prematurity can be most impressive in very  low 
birth weight premature infants (2). This group of 
patients appears to be one that might benefit from 
immunoglobulin therapy. Thus it was very timely 
for Drs. Gerald Fischer and Carol Baker to pre- 
sent their experiences with IVIG therapy for neo- 
natal sepsis in the premature infant. 
In 1981, Dr. Richard Stiehm's group from the 
University of California at Los Angeles presented 
their findings on the oral administration of IVIG in 
premature infants as a specific modality in the 
prevention or treatment of enteric infections (3). 
This work was shortly followed by the observa- 
tions of Dr. Barnes and co-workers from Australia 
on the use of human immune serum globulin by the 
oral route in the treatment of low birth weight 
infants with rotavirus-associated diarrhea (4). Drs. 
Warren Strober and Randall Goldblum reviewed 
the cellular and humoral aspects of  mucosal gut 
immunity, respectively. Drs. Martha Eibl, Robert 
Yolken, and Peter Tutschka each presented their 
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work on the potential therapeutic applications of 
orally administered immune serum globulin, either 
as specific therapy of enteric pathogens or as 
prophylactic regimens in patients undergoing bone 
marrow transplantation. 
As can be seen from the foregoing outline, this 
symposium takes that first step in moving forward 
with the concept of immunoglobulin therapy in 
exploring new potential clinical applications, new 
potential routes of administration, and, more im- 
portantly, the potential applications of monoclonal 
antibodies and genetically engineered monoclonal 
antibodies in the treatment of a variety of clinical 
disorders. 
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